OTC$LIANY
Lianbio-Adr · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
LianBio reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
LianBio reported a net loss of $27.7 million for the first quarter of 2022, with research and development expenses at $12.3 million and general and administrative expenses at $16.1 million. The company's cash balance totaled $389.1 million, projected to fund operations through mid-2024.
- Partner Bristol Myers Squibb received U.S. FDA approval of mavacamten for oHCM treatment.
- Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM is ongoing.
- Partner Tarsus announced positive topline data from the Phase 3 Saturn-2 clinical trial of TP-03 in patients with Demodex blepharitis.
- Three additional pipeline programs are expected to enter Phase 3 clinical trials in China by year-end 2022.
Headline financials
Revenue & EPS history
Lianbio-Adr · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2022
+8.4%
Avg return
Earnings day
+8.4%
Avg return
5 days after
-3.1%
Avg return
30 days after
77%
10 / 13 earnings
Positive
+17.7%
Q4 2020
Best reaction
-4.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | -2.2% | -6.7% | -7.4% | |
| Q3 2023 | +0.7% | +1.5% | +4.2% | |
| Q2 2023 | +2.7% | +0.0% | -9.7% | |
| Q1 2023 | -4.1% | +4.6% | +17.7% | |
| Q4 2022 | -1.2% | +17.4% | +18.0% | |
| Q3 2022 | +17.5% | +38.9% | +7.1% | |
| Q2 2022 | +11.1% | -1.5% | -3.0% | |
| Q1 2022 | +9.3% | +29.8% | +28.4% | |
| Q4 2021 | +3.9% | +26.1% | +7.3% | |
| Q2 2021 | +17.7% | +0.4% | -17.3% | |
| Q3 2021 | +17.7% | +0.4% | -17.3% | |
| Q4 2020 | +17.7% | +0.4% | -17.3% | |
| Q1 2021 | +17.7% | -2.4% | -50.4% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro